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The expiration of patents on many biological medicinal products has prompted the development of these
products as similar biological (biosimilar) products. The standard approach of demonstration of bio-
equivalence for chemical generic products is scientiﬁcally not applicable for biosimilar products. The
biosimilar product approach, based on comparability (demonstration of similarity), should be adopted. In
view of the impending submissions and to facilitate access of such products at a more affordable price in
Singapore, the Health Sciences Authority (HSA) formalised the procedures and requirements for regis-
tration of biosimilar products in 2009. HSA has published the “Guideline on Registration of Similar
Biological Products in Singapore” which describes the basic principles, submission procedure, and
requirements pertaining to documentation, pharmacovigilance, and post-approval batch release for the
registration of biosimilar products. This article provides a brief overview as well as key points on the
registration of medicinal products and biosimilar products in Singapore.
 World Health Organization 2011. All rights reserved. The World Health Organization has granted the
Publisher permission for the reproduction of this article.1. Introduction
Biological medicinal products are produced using a living
system or organism. They are different from traditional chemical
medicinal products in many ways. The manufacturing process of
a biological medicinal product is highly complex and is a deter-
mining factor in the development of a biological medicinal product.
The deﬁnition of “process” includes the type or identity of the
source material and the individual process steps in cell fermenta-
tion, protein puriﬁcation, sterile ﬁlling and drug product formula-
tion. Minute process changes can result in signiﬁcant differences in
the clinical properties of the biological medicinal products.
Many biological medicinal products have been demonstrated to
be successful in the treatment and management of life-threatening
diseases. However, the high cost of such medicinal products may
have limited their use. The expiration of the patents on many
biological medicinal products has prompted the development of
these products as similar biological (biosimilar) products. A bio-
similar product will have an abbreviated non-clinical and clinical
development programme leveraging on the existing information of
the original product and focusing on demonstration of similarity
with the original product. While the launch of such biosimilarþ65 6478 9032.
AM_Kai_Tong@hsa.gov.sg (K.
ll rights reserved. The World Healthproducts will provide patients with potentially cheaper alterna-
tives, it is also prudent to ensure that the quality, safety and efﬁcacy
of such products are not compromised.2. Registration of medicinal products in Singapore
The Health Sciences Authority (HSA) is the licensing authority
for medicinal products in Singapore. The Health Products Regula-
tion Group (HPRG) of HSA regulates health products in Singapore to
ensure that their quality, safety and efﬁcacy meet internationally
benchmarked standards. The licensing of medicinal products for
sale and supply in Singapore, including pharmaceutical and bio-
logical medicinal products, is governed by legislative requirements
under the Medicines Act (Chapter 176) (1977).
Pre-market evaluation is conducted to determine the risk versus
beneﬁt proﬁle of medicinal products before registration and HSA
adopts a risk-based approach with application of current interna-
tional guidelines, standards and scientiﬁc knowledge. HSA has
implemented three evaluation routes for new drug applications
after taking into consideration the inherent risk of the product and
following the conﬁdence built upon prior approvals by HSA’s
reference agencies. The reference agencies for medicinal products
are namely Australia Therapeutic Goods Administration (TGA),
European Medicines Agency (EMA), Health Canada, United
Kingdom Medicines and Healthcare products Regulation Agency
(MHRA), and United States Food and Drug Administration (FDA).Organization has granted the Publisher permission for the reproduction of this article.
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robustness in the evaluation system. The depth of evaluation varies
according to a conﬁdence-based approach, and enhanced efﬁciency
is obtained by leveraging on the evaluations conducted by the
reference agencies. The three evaluation routes are:
a. The Full dossier evaluation route is applicable to a product that
has not been approved by any drug regulatory agency at the
time of submission. The complete quality, non-clinical and
clinical documentation is evaluated.
b. The Abridged dossier evaluation route is applicable to
a product that has been approved by at least one drug regu-
latory agency at the time of submission. The complete quality
and abridged clinical documentation is evaluated.
c. The Veriﬁcation dossier evaluation route is applicable to
a product that has been approved by at least two of HSA’s
reference agencies. The evaluation leverages on the review
conducted by the reference agencies.
At the time of market approval for a medicinal product, infor-
mation on the safety of the product is relatively limited and there
are some potential risks which may not have been identiﬁed.
Consequently, all medicinal products need to be continually
assessed for safety within the context of their perceived beneﬁts via
pharmacovigilance activities.
In Singapore, subsequent entry of a biological product
leveraging on the dataset provided by a reference biological
product is known as a biosimilar product. Such biosimilar products
will require a submission which is similar to that of a new drug
application whereby for it to be evaluated, it should have been
approved by at least one of HSA’s reference agencies.
3. Registration of similar biological (biosimilar) products in
Singapore
The “Guidance on Registration of Similar Biological (Biosimilar)
Products in Singapore” was developed in consultation with the
industry stakeholders and came into effect on 1st August 2009 [1].
The guideline was based mainly on the European Medicines
Agency’s guidelines on biosimilar products (“CHMP Guideline on
Similar Biological Medicinal Products”, “CHMP Guideline on Similar
Biological Medicinal Products Containing Biotechnology-Derived
Proteins as Active Substance: Quality Issues”, “CHMP Guideline on
Comparability of Medicinal Products Containing Biotechnology-
Derived Proteins as Active Substance: Quality Issues”, and CHMP
Guideline on Similar Biological Medicinal Products Containing
Biotechnology-Derived Proteins as Active Substance: Non-Clinical
and Clinical Issues”), with consideration of Singapore’s local regu-
latory environment [2e5]. The basic principles in the guideline are
also similar to that in the “WHOGuidelines on Evaluation of Similar
Biotherapeutic Products (SBPs)” [6].
3.1. Biosimilar approach
A biosimilar product is intended to be similar in terms of quality,
safety and efﬁcacy to a registered biological product (reference
biological product), for which there is substantial evidence of safety
and efﬁcacy.
The standard generic approach of bioequivalence demonstra-
tion with reference to a chemically-derived drug product is scien-
tiﬁcally not appropriate for biosimilar applications, since biological
drugs are much more complex in their structure and inherent
properties as compared to chemically-derived drugs. The biosimilar
product approach, based on comparability (demonstration of
similarity), should be followed.The development of a biosimilar product involves stepwise
comparability exercises starting with comparison of the quality
characteristics of the biosimilar product and the reference product.
Demonstration of similarity in terms of quality is a prerequisite for
the reduction of the non-clinical and clinical dataset required for
registration. If relevant differences are found in the quality, non-
clinical and/or clinical studies, the product will not likely qualify
as a biosimilar product andmore extensive non-clinical and clinical
datasets will likely be required to support registration.
3.2. Choice of reference product
The chosen reference biological product must be registered in
Singapore and a biosimilar product cannot be used as a reference
product. The reference product should be of the corresponding
strength and from the same drug product manufacturing site as the
Singapore reference product. The same reference product should be
used throughout the comparability assessment for quality, safety
and efﬁcacy studies during the development of a biosimilar product
in order to allow the generation of coherent data and conclusions.
The active substance of the biosimilar product and the reference
product should be similar in molecular and biological terms. The
pharmaceutical form and route of administration of the biosimilar
product should be the same as that of the reference product.
3.3. Submission procedure and requirements
The application for a biosimilar product is to be submitted as
a newdrug applicationvia theabridgeddossier evaluation route. The
pre-requisites for the biosimilar product is that it has to be evaluated
and approved as a biosimilar product by at least one of HSA’s refer-
ence agencies, namely, Australia TGA, Health Canada, EMA, and US
FDA. General procedures and requirements for submission are
similar to that for a new biological product and the details are in the
“Guidance on Medicinal Product Registration in Singapore” [7].
The complete quality documentation for both the drug
substance and drug product is required. Comparability data
between the biosimilar product and the reference product is
essential. The extent of the comparability studies and the product
class speciﬁc assessment criteriawill depend on the type of biologic
molecule and the analytical method available to demonstrate
comparability. Product speciﬁc biosimilar guidelines for seven
classes of biological products (recombinant human insulin, growth
hormone, recombinant granulocyte-colony stimulating factor,
recombinant erythropoietins, recombinant interferon alpha, low-
molecular-weight-heparins and monoclonal antibodies) had been
published by EMA while product speciﬁc guidelines for recombi-
nant interferon beta and recombinant follicle stimulation hormone
are still under development [8e14].
Non-clinical documentation should include comparative studies
designed to detect differences in the response between the bio-
similar product and the reference product. Requirements generally
include in vitro studies to establish comparability in reactivity as
well as animal studies to investigate pharmacodynamic effects and
non-clinical toxicity. Normally other routine toxicological studies
such as safety pharmacology, reproduction toxicology, mutage-
nicity and carcinogenicity studies are not required, unless indicated
by the results of repeat dose studies.
Clinical comparability studies should be generated with the test
product produced with the ﬁnal manufacturing process repre-
senting the quality proﬁle of the batches to be commercialised. Any
deviation is to be justiﬁed and supported by adequate data. The
clinical comparative exercise should begin with pharmacokinetic
and pharmacodynamic studies followed by clinical efﬁcacy and
safety studies.
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investigated. The extent of independent testing neededwill depend
on a variety of scientiﬁc factors such as the indication of whether
the product is to be administered for chronic conditions, the overall
assessment of the product’s immunogenic potential, and whether
there is the possibility of generating a cross-reaction with an
important endogenous molecule.
The conditions of use for the biosimilar product must fall within
the directions for use including indication(s), dosing regimen(s) and
patient group(s) for the Singapore reference product. In case the
reference medicinal product has more than one indication, the efﬁ-
cacy and safety of the biosimilar product has to be justiﬁed or, if
necessary, demonstrated separately for each of the claimed indica-
tions. In certain cases, it may be possible to extrapolate therapeutic
similarity shown in one indication to other indications of the refer-
ence medicinal product with appropriate scientiﬁc justiﬁcation.
3.4. Interchangeability and substitution
A biosimilar product is normally approved to be interchangeable
with the reference product. To establish that two products would
be substitutable, the applicant of a biosimilar product would need
additional clinical data. Awarning statement on the risks associated
with switching of products during treatment, and against product
substitution, is to be included in the package insert of the biosimilar
product.
3.5. Pharmacovigilance
At the time of market approval for a medicinal product, infor-
mationon the safetyof theproduct is relatively limited, and there are
some potential risks which may not have been identiﬁed. For bio-
similar products, there is also the concern on potential immunoge-
nicity issues. Therefore, post-marketmonitoring of clinical safety for
biosimilar products is necessary as with all medicinal products, with
focus on the speciﬁc concerns for biosimilar products.
The applicant is required to submit a risk management plan at
the time of application for product licensure. The aim of the plan is
to mitigate potential risks associated with the biosimilar product.
The applicant should also provide additional educational materials
to the physicians and patients to provide themwith information on
the speciﬁc or potential risks of the biosimilar product and
measures on how to recognise or reduce them.
3.6. Post-approval batch release requirements
Biosmilar products would be subjected to a risk-based post-
approval batch release programme. The product licence holder
would be required to submit batch quality documents prior to
import and sale of each batch of biosimilar product for evaluation.
The batch release documents include the manufacturer’s batch
release data and certiﬁcate of analysis. The licence holder is also
required to update HSA on the stability data of the batch of product
selected each year to be part of the stability study program for the
drug product. HSA may choose to request additional documents or
to carry out independent batch testing of selected batches, if
deemed necessary.
4. Conclusion and next steps
The concept of licensing products via the biosimilar approach is
a new regulatory area and the guidelines for the evaluation andregulation of biosimilar products globally are still rather limited
and constantly evolving. Moving forward, experience and expertise
in the regulation of biosimilars will need to be built up and the
sharing of experience at an international platform would be an
important avenue to improve the understanding of biosimilars. The
requirements and principles on regulation of biosimilars will also
need to be constantly reﬁned with the advancement of science and
technology.
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